SCHEMBL1628797

SCHEMBL1628797

COCCC(=O)Nc1ccc(-n2nccc2-c2ccc(O)cc2O)cc1

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
AAK1 Q2M2I8 1/20 0.43
CECR2 Q9BXF3 1/20 0.39
KDM4E B2RXH2 1/20 0.38
BRAF P15056 1/20 0.38
EGLN2 Q96KS0 1/20 0.38
NPSR1 Q6W5P4 2/20 0.37
ALDH1A1 P00352 1/20 0.37
NR3C2 P08235 1/20 0.37
MALT1 Q9UDY8 7/20 0.36
CNR1 P21554 1/20 0.36
CNR2 P34972 1/20 0.36
NCOA1 Q15788 1/20 0.36
NCOA3 Q9Y6Q9 1/20 0.36
MAPK8 P45983 1/20 0.36
MAPK10 P53779 1/20 0.36
RIPK2 O43353 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1630372 0.88 TP53 (0.47) AAK1KDM4ENPSR1ALDH1A1CNR1
SCHEMBL1631466 0.86 ALDH1A1 (0.47) AAK1KDM4ENPSR1ALDH1A1
SCHEMBL1629168 0.82 MAPT (0.46) KDM4EALDH1A1NR3C2
SCHEMBL1630414 0.81 KDM4E (0.51) KDM4EALDH1A1
SCHEMBL1628802 0.80 NR3C2 (0.37) KDM4ENPSR1ALDH1A1NR3C2
SCHEMBL1629986 0.78 GAA (0.50) KDM4E
SCHEMBL1629510 0.78 TYR (0.48) KDM4E
SCHEMBL1629945 0.77 NPC1 (0.52) KDM4EALDH1A1
SCHEMBL1629515 0.75 ALDH1A1 (0.44) ALDH1A1NR3C2MALT1
SCHEMBL1628955 0.75 MEN1 (0.44) ALDH1A1MAPK10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1776346-B1 1,5-Diphenylpyrazoles MERCK PATENT GMBH (DE) 2013-06-26 EP disclosed
US-7932401-B2 Heat Shock Protein 90 (HSP90) inhibitors; 5-(2-hydroxy-4-methoxyphenyl)-1-(3-nitrophenyl)-1H-pyrazole for example; antitumor agent, viral diseases, transplant rejection, cystic fibrosis, angiogenesis inhibition, infectious, autoimmune, or inflammatory diseases, ischemia, chemotherapy cytoprotectant MERCK PATENT GMBH (DE) 2011-04-26 US disclosed
US-20080085904-A1 1,5-Diphenylpyrazoles MERCK PATENT GMBH (DE) 2008-04-10 US disclosed
EP-1776346-A1 1,5-DIPHENYLPYRAZOLES Merck Patent GmbH (DE) 2007-04-25 EP disclosed
WO-2006018082-A1 1,5-DIPHENYLPYRAZOLES MERCK PATENT GMBH (DE) 2006-02-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080085904-A1 1,5-Diphenylpyrazoles HSP90AB1, HSP90AA1, HSP90AB2P AAK1 2324/4885CECR2 2162/4885KDM4E 3577/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.